Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Bruce Cozadd Sells 77,500 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 77,500 shares of the business’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the sale, the director owned 393,332 shares of the company’s stock, valued at $69,938,362.92. The trade was a 16.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jazz Pharmaceuticals Trading Down 2.5%

NASDAQ JAZZ opened at $172.12 on Tuesday. The firm has a market capitalization of $10.46 billion, a price-to-earnings ratio of -25.57, a PEG ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99. The company’s 50 day moving average price is $144.71 and its 200 day moving average price is $125.74.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on JAZZ. Wells Fargo & Company upped their price target on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday, November 17th. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Finally, Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $195.67.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $127,344,000. Nuveen LLC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth $62,362,000. Fuller & Thaler Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after buying an additional 391,660 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in Jazz Pharmaceuticals by 592.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after acquiring an additional 373,383 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after acquiring an additional 304,463 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.